Work

A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in castrate-resistant prostate cancer and certain other immunologically cold tumors.

Year: 2023

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2023.41.6_suppl.tps293

Authors: Jonathan Alexander Chatzkel, Ji-Hyun Lee, Azka Ali, Carmen Joseph Allegra, Wayne Brisbane, Paul Crispen, Padraic O'Malley, Thomas J. George, Brian Hemendra Ramnaraign

Institutions: University of Florida, UF Health Cancer Center

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: University of Florida

OpenAlex ID: W4324136994

Cites:

Cited by:

Related to: 10